Ibio Inc
NASDAQ:IBIO

Watchlist Manager
Ibio Inc Logo
Ibio Inc
NASDAQ:IBIO
Watchlist
Price: 2.135 USD -10.67% Market Closed
Market Cap: $48m

Net Margin

-4 594.3%
Current
Improving
by 23 213.8%
vs 3-y average of -27 808.1%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-4 594.3%
=
Net Income
$-18.4m
/
Revenue
$400k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-4 594.3%
=
Net Income
$-18.4m
/
Revenue
$400k

Peer Comparison

Country Company Market Cap Net
Margin
US
Ibio Inc
NASDAQ:IBIO
53.8m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
393.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
172.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
88.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.4B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 15 072 companies
5th percentile
-4 594.3%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Ibio Inc
Glance View

Market Cap
48m USD
Industry
Biotechnology

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. The company is headquartered in New York City, New York and currently employs 105 full-time employees. The company went IPO on 2008-08-18. The firm is focusing its technologies on the research and development of novel products at its Drug Discovery Center in California. The firm through its FastPharming Manufacturing System and GlycaneeringSM Technologies develop its portfolio of proprietary biologic drug candidates. The firm operates through two segments: Biopharmaceuticals, and Bioprocessing. Its Biopharmaceuticals segment is engaged in large molecule discovery, development, and licensing activities. Its Bioprocessing segment is engaged in contract development and manufacturing services for recombinant proteins. Its pipeline includes IBIO-100, IBIO-101, IBIO-202, and IBIO-400. Its subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with GlycaneeringSM Development Services.

IBIO Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-4 594.3%
=
Net Income
$-18.4m
/
Revenue
$400k
What is Ibio Inc's current Net Margin?

The current Net Margin for Ibio Inc is -4 594.3%, which is above its 3-year median of -27 808.1%.

How has Net Margin changed over time?

Over the last 3 years, Ibio Inc’s Net Margin has decreased from -2 680.3% to -4 594.3%. During this period, it reached a low of -105 240% on Sep 30, 2023 and a high of -2 680.3% on Jun 30, 2022.

Back to Top